European Neuropsychopharmacology (v.20, #S1)
P.3.006 The relationship between 5-HTTLPR polymorphism and hippocampal volumes in medication-free depressed patients by M.C. Eker; H. Okur; O. Kitis; O. Donat-Eker; E. Ozan; N. Akarsu; A.S. Gonul (S66-S67).
P.3.007 Abnormalities in reward prediction error signals in depression and schizophrenia by V.B. Gradin; P. Kumar; G. Waiter; T. Ahearn; I. Reid; C. Stickle; M. Milders; J. Hall; J.D. Steele (S67-S68).
P.3.005 Antidepressant treatment modulates neural responses to self-referential words in subjects with high neuroticism by M. Di Simplicio; R. Norbury; C.J. Harmer (S65-S66).
P.3.004 Effect of tryptophan depletion and loading on the response to double breath 35% CO2 challenge in healthy volunteers by A. Colasanti; G. Esquivel; E. den Boer; A. Horlings; K. Schruers; E.J. Griez (S64-S65).
P.3.002 Placebo response in trials for acute mania: a double-edged sword by M. Bonnin; A. Yildiz; R.J. Baldessarini; E. Vieta (S63).
P.3.003 Involvement of the endocannabinoid system in working memory: a pharmacological MRI study with delta9-THC by M.G. Bossong; H.H. van Hell; G. Jager; F.A. Oudman; R.S. Kahn; N.F. Ramsey (S64).
P.3.008 Acute tryptophan depletion increases cingulate cortex reactivity in recovered depressed patients by J. Horder; P. Cowen; M. Browning; S. McTavish; C.J. Harmer (S68-S69).
P.3.009 Effects of naltrexone on amphetamine-induced changes in the brain dopamine system by N. Jayaram-Lindström; J. Haggkvist; C. Halldin; B. Schilström; A.L. Nordström; J. Franck (S69-S70).
P.3.013 Interaction between alcohol and opioids in opioid-dependent subjects by R. Lees; T. Williams; G. Henderson; M. Hickman; A. Lingford-Hughes (S73-S74).
P.3.014 Long term follow up of adolescent depression: history of drug prescriptions by A. Päären; H. Bohman; U. Jonsson; A.L. von Knorring; L. von Knorring (S74).
P.3.012 Corticostriatal white matter development is changed in autism by M. Langen; R.C.W. Mandl; H.E. Hulshoff Pol; H. van Engeland; S. Durston (S72-S73).
P.3.011 Visual information processing abnormalities as biomarker of schizophrenia: an EEG study in schizotypy by I. Koychev; W. El-Deredy; C. Haenschel; J.F.W. Deakin (S71-S72).
P.3.010 CYP2D6 and CYP2C19 genotypes predict antidepressant dose in the GENDEP project by R. Keers; M. Ingelman-Sundberg; J. Hauser; W. Maier; M. Rietschel; O. Mors; P. McGuffin; A.E. Farmer; I.W. Craig; K.J. Aitchison (S70-S71).
P.3.001 Serotonin transporter (SERT) availability in raphe nuclei quantified with PET predicts treatment response to S-citalopram in major depressive disorder by E. Akimova; R. Lanzenberger; M. Savli; D. Häusler; W. Wadsak; C. Spindelegger; U. Moser; M. Fink; K. Kletter; S. Kasper (S62-S63).
S.3.02 Mechanisms of placebo and placebo related effects across diseases and treatments by F. Benedetti (S60-S61).
P.2.029 The effect of neonatal serotonin depletion on reinforcing potential of psychoactive substances and natural reward by P. Rok-Bujko; P. Krzascik; R. Stefanski; W. Kostowski (S52-S53).
P.2.030 Influence of UFP-101 central infusion on behavioural and cellular effects in a chronic stress model in the rat by V. Ruggieri; G. Vitale; M. Filaferro; S. Zucchini; M. Simonato; C. Cifani; M. Massi (S53-S54).
P.2.028 Aversive taste memory augmentation following NMDA receptor antagonist administration by L. Ramirez-Lugo; G. Wegener; M.J. West; S.J. Morten (S51-S52).
P.2.027 Is the brain a special compartment with respect to free corticosterone? A dual probe in vivo microdialysis study in rats by X. Qian; S.K. Droste; S.L. Lightman; J.M.H.M. Reul; A.C.E. Linthorst (S50-S51).
P.2.026 Serotonin–dopamine interaction in reward: microdialysis and intracranial self-stimulation by J. Prins; R. Dupree; G.A.H. Korte-Bouws; B. Olivier; S.M. Korte (S50).
P.2.031 Neonatal estradiol administration to female rats alters adult benzodiazepine sensitivity by F. Santoru; A. Calza; C. Sogliano; R. Berretti; M. Langiu; G. Biggio; A. Concas (S54).
P.2.032 Intranasal administration of arginine vasopressin enhances acute stress response in social encounters by I. Shalev; S. Israel; F. Uzefovsky; M. Kaitz; R.P. Ebstein (S54-S55).
P.2.036 Effects of acute lorazepam on functional connectivity and electroencephalography: a pharmacological fMRI/EEG study by B.T. Wollweber; S.A. Kiem; D. Hoehn; K. Andrade; V. Spoormaker; F. Holsboer; M. Czisch; P.G. Sämann (S58).
S.3.01 New uses of MRI in psychiatry by N.F. Ramsey (S59-S60).
P.2.035 Alcohol dehydrogenase 4 knock-out mice as a model of dopamine-system related dysfunction by M. Westerlund; A. Carmine Belin; A. Anvret; E. Lindqvist; K. Pernold; S.O. Ögren; G. Duester; D. Galter (S57).
P.2.034 Wrong expectations? Expectancy coding of gains and losses in alcohol dependent subjects and pathological gamblers by R.J. van Holst; A.E. Goudriaan; D.J. Veltman; W. van den Brink (S56-S57).
P.2.033 Environmental manipulation influences depression-like behaviour in genotype dependent manner by M. Sikora; W. Solecki; J. Kubik; R. Przewlocki (S55-S56).
P.3.015 Community treatment orders, ethnicity, conditions and psychotropic medication: the first six months (N = 126) by M.X. Patel; J. Matonhodze; J. Gilleen; J. Boydell; D. Taylor; G. Szmukler; T.J. Lambert; A.S. David (S74-S75).
P.3.016 Temporal lobe grey matter volume in schizophrenia is influenced by glycogen synthase kinase 3-beta activity by S. Poletti; D. Radaelli; C. Lorenzi; E. Smeraldi; F. Benedetti (S75-S76).
P.4.004 Stress-induced alterations in hippocampal microRNAs: effects of lithium by R.M. O'Connor; O.F. O'Leary; A. Dinan; S. Grenham; T.G. Dinan; J.F. Cryan (S93).
P.4.005 Differential response to treatment across countries in a randomized clinical trial in mania by I. Pacchiarotti; E. Pappdopulos; F. Mandel; I. Lombardo; A. Loebel; E. Vieta (S93-S94).
P.4.003 TRPC6 channel activation by hyperforin, the antidepressant active constituent of St. John's wort, induces neurite outgrowth by J.H. Heiser; W.E. Müller; K. Leuner (S92).
P.4.002 Mismatch negativity and executive functions in schizophrenia and bipolar disorder by N. Domján; G. Csifcsák; I. Szendi; Z. Janka (S91-S92).
P.4.001 Phenomenology and 24 month treatment outcome of pediatric bipolar disorder by S. Carucci; P. Atzori; C. Balia; F. Danjou; A. Zuddas (S90-S91).
P.4.006 Students scoring highly on the mood disorder questionnaire show increased dorsolateral prefrontal cortex (DLPFC) activity to threatening words by P.L. Rock; G.M. Goodwin; C.J. Harmer (S94-S95).
P.4.007 Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients by A. Rosa; C. Torrent; A. Martínez-Áran; C. Daban; B. Amann; V. Balanzá-Martínez; C.M. Bonnin; N. Cruz; R. Tabarés-Seisdedos; E. Vieta (S95-S96).
Author Index (S99-S102).
Keyword Index (S103-S104).
P.4.010 Serotonin inhibits field potentials in the medial prefrontal cortex by J. Wallace; R. McQuade; H.M. Marston; S.E. Gartside (S97-S98).
P.4.009 Cognitive dysfunction in bipolar patients: association with depressive symptoms and alcohol use by M.J. van der Werf-Eldering; H. Burger; E.A.E. Holthausen; A. Aleman; W.A. Nolen (S96-S97).
P.4.008 Inositol monophosphatase: drug target or false alarm? by N. Singh; S. Vasudevan; J. Thomas; P. Aley; T. Sharp; G. Churchill (S96).
S.4.02 Current status and unmet needs of treatment in bipolar disorders by A. Young (S89-S90).
S.4.01 Molecular drug targets for bipolar disorders by H. Manji (S87-S89).
P.3.020 Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton MRS study by M.J. Taylor; E.R. Tiangga; R.N. Mhuircheartaigh; P.J. Cowen (S79).
P.3.021 Long acting naltrexone implants for heroin dependence by A. Tiurina; E. Krupitsky; E. Zvartau; G. Woody (S79-S80).
P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis by R. Smieskova; P. Fusar-Poli; P. Allen; K. Bendfeldt; R.D. Stieglitz; J. Drewe; P.K. McGuire; A. Riecher-Rössler; S.J. Borgwardt (S78).
P.3.018 Mirtazapine reduces neural responses to fearful faces in healthy volunteers by N.B. Rawlings; R. Norbury; P.J. Cowen; C.J. Harmer (S77-S78).
P.3.017 Acute low dose tryptophan depletion in volunteers at high risk for eating disorders by A. Pringle; M.J. Cooper; M. Browning; C.J. Harmer (S76-S77).
P.3.022 Initial antidepressant monotherapy in bipolar depression is associated to more suicide attempts and switch into mania by M. Valentí; I. Pacchiarotti; A.M.A. Nivoli; A. Murru; F. Colom; E. Vieta (S80-S81).
P.3.023 Exploring the functional brain network: how efficient is our brain? by M.P. van den Heuvel; H.E. Hulshoff Pol (S81).
P.3.027 Oxcarbazepine, gabapentin and lamotrigine in treatment of heroin craving by N. Zivkovic; D. Pavicevic; G. Djokic (S84-S85).
P.3.028 Somatisation in major depression, genetic association and clinical features by T. Klengel; A. Heck; H. Pfister; J.M. Hennings; A. Menke; S. Lucae; F. Holsboer; M. Ising (S85-S86).
P.3.026 Intranasal oxytocin in patients with post traumatic stress disorder: a single dose, pilot double blind crossover study by U. Yatzkar; E. Klein (S84).
P.3.025 Electroencephalographic measures as predictors of methylphenidate response in attention-deficit/hyperactivity disorder by A.E. Wester; K.B.E. Böcker; H. Van Engeland; J.L. Kenemans (S83).
P.3.024 Addiction proneness: contribution of the endocannabinoid system and reward processing by H.H. van Hell; G. Jager; A. Brouwer; M.G. Bossong; R.S. Kahn; N.F. Ramsey (S82).
P.2.025 Neural circuitry underlying GABA-B receptor positive modulator-induced effects on anxiety behaviour in the mouse by R.C. Pizzo; A.L. Cucinotta; J.F. Cryan (S49).
P.2.024 Attenuation by paroxetine and D-cycloserine of the deficit in cognitive processes following acute stress: an animal model of PTSD by J. Philbert; P. Pichat; R. Santamaria; B. Biton; O. Bergis; P. Avenet; G. Griebel (S48-S49).
P.1.019 Involvement of brain galanin systems in response to acute and chronic inescapable stress and antidepressant treatment by E. Kuteeva; T. Hökfelt; S.O. Ögren (S17).
P.1.020 A coding variant of the novel serotonin receptor subunit 5-HT3E influences sustained attention in schizophrenia patients by L. Lennertz; R. Mössner (S17-S18).
P.1.017 Netrin G1 polymorphisms in cocaine and alcohol codependence vulnerability: from mice to men by S. Kelai; G. Maussion; N. Munoz; C. Boni; N. Ramoz; M. Simonneau; P. Gorwood (S16).
P.1.016 Association of the adrenergic receptor alpha1β with antidepressant treatment in the MARS study by S. Horstmann; A. Menke; V. Straub; J. Hennings; S. Lucae; S. Wollweber; E.B. Binder (S15-S16).
P.1.014 Identification of a mouse febrile seizure susceptibility gene by E.V.S. Hessel; M.J.H. Kas; H.A. van Lith; I.G. Wolterink-Donselaar; M. de Wit; P.N.E. de Graan (S13-S14).
P.1.015 Long-term fluoxetine reverses alpha2-adrenoceptors desensitization induced by chronic corticosterone treatment by I. Horrillo; J.E. Ortega; J.J. Meana (S14-S15).
P.1.021 Low CD38 gene expression in lymphoblastoid cells and in haplotypes is associated with autism spectrum disorders by E. Lerer; N. Yirmiya; S. Salomon; R.P. Ebstein (S18-S19).
P.1.022 Amyloid aggregation is critical for the interaction with neuronal nicotinic acetylcholine receptors (nAChRs) – implications for neuroprotection in Alzheimer's disease by A.M. Lilja; O. Porras; E. Storelli; A. Nordberg; A. Marutle (S19-S20).
P.1.026 Mapping of anxiogenic neuronal profiles induced by the GABA inverse agonist FG-7142 and caffeine using pharmacological magnetic resonance imaging by S. Sekar; J.M. Raley; A.S. Lowe; T. Sharp; N.R. Sibson; A.M. Blamire; T. Steckler; M. Shoaib (S23).
P.1.027 Cued but not contextual fear conditioning impairment in the NMDA receptor subunit NR1-DbhCre transgenic mice by W. Solecki; K. Szklarczyk; J. Kubik; M. Sikora; J. Rodriquez Parkitna; G. Schütz; R. Przewlocki (S23-S24).
P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder by A. Saricicek; I. Esterlis; B. Ruf; K. Maloney; A. Muralidharan; J. Seibyl; G. Tamagnan; F. Bois; J. Staley; Z. Bhagwagar (S22).
P.1.024 Depressive disorder moderates the effect of fat mass and obesity-associated gene (FTO) on body mass index (BMI) by M. Rivera; S. Cohen-Woods; G. Breen; A.W. Butler; A. Korszun; C.M. Lewis; R. Uher; I. Craig; A.E. Farmer; P. McGuffin (S21-S22).
P.1.023 Effect of antidepressants on lipopolysaccharide-induced interleukin-1β levels in brain and plasma of rats by A. Prymus; E. Obuchowicz; A. Bielecka; L. Drzyzga; M. Kot; W.A. Daniel; I. Krupka-Matuszczyk (S20-S21).
P.1.013 Glycogen synthase kinase-3β inhibition blocks the effect of IL-1β on hippocampal neural precursor cell differentiation by H. Green; Y. Nolan (S13).
P.1.012 Serum brain-derived neurotrophic factor levels as predictor of antidepressant therapy response by M. Giese; J. Beck; S. Brand; F. Muheim; M. Hatzinger; E. Holsboer-Trachsler; A. Eckert (S12).
P.1.003 Clinical and genetic predictors of worsening after aripiprazole switch: results from a randomised open study by A. Chiesa; C.U. Pae; L. Mandelli; D. De Ronchi; A. Serretti (S4-S5).
P.1.004 Increased affinity of autoantibodies directed against a melanocyte stimulating hormone in patients with bulimia nervosa by Q. Coquerel; M. Hamze-sinno; M. Coëffier; D. Gilbert; H. Schioth; T. Haitina; P. Déchelotte; S.O. Fetissov (S5).
P.1.002 The histamine site of the NMDA receptor: a new target to increase NMDA receptor function by A. Burban; R. Faucard; V. Armand; C. Bayard; V. Vorobjev; J.M. Arrang (S3-S4).
P.1.001 Chronic clozapine treatment reduces reelin expression in the rat prefrontal cortex by A. Basu; K. Sugden; K. Tandon; C. Fernandes; E.M. Tsapakis; J. Stephenson; K.J. Aitchison (S2-S3).
S.1.02 The neuropharmacology of impulsive behaviour with focus on translational aspects by T. Pattij; A.N.M. Schoffelmeer (S1-S2).
P.1.005 Glutamatergic gene variants impact the side effects and antipsychotic efficacy of haloperidol by A. Drago; I. Giegling; M. Schäfer; A.M. Hartmann; T. Sander; M.R. Toliat; H.J. Moller; H.H. Stassen; D. Rujescu; A. Serretti (S6).
P.1.006 Neurogenic and chronic behavioural effects of fluoxetine are attenuated in p11 KO mice by M. Egeland; J. Warner-Schmidt; P. Greengard; P. Svenningsson (S6-S7).
P.1.010 Repeated brain stimulation affects markers for neuroplasticity: differential outcomes in anaesthetized and awake animals by R. Gersner; E. Kravetz; O. Levit; A. Zangen (S10-S11).
P.1.011 ADRA2B genotype moderates the effect of catechol-O-methyltransferase genotype on episodic memory performance by A.A. Gibbs; K. Naudts; R. Azevedo; A.S. David (S11-S12).
P.1.009 Mice with decreased vesicular glutamate transporter VGLUT1 levels show an altered presynaptic 5-HT function by A.L. García-García; N. Elizalde; E. Venzala; J. Del Rio; L. Lanfumey; R.M. Tordera (S9-S10).
P.1.008 Evaluation of the endocannabinoid system in post-mortem human prefrontal cortex of alcoholic subjects by A.M. Erdozain; S.P.H. Alexander; D.A. Kendall; E.M. Valdizan; J.J. Meana; L.F. Callado (S8-S9).
P.1.007 Levels of activators of cyclin-dependent protein kinase 5 (Cdk5) p25 and p35 in Alzheimer's disease by O. Engmann; T. Hortobagyi; A. Thompson; K.P. Giese (S7-S8).
P.1.028 Altered functional connectivity of the amygdala in social anxiety disorder by P. Stein; A. Weissenbacher; A. Hahn; F. Gerstl; C. Windischberger; E. Moser; S. Kasper; R. Lanzenberger (S24-S25).
P.1.029 Vagus nerve stimulation induces cell proliferation and changes in neuronal morphology in the rat hippocampus by C. Utzeri; F. Biggio; P. Olla; P. Follesa; G. Biggio (S25-S26).
P.2.015 Antiparkinsonian effects of H3 receptor inverse agonists: a behavioural study with ciproxifan in the 6-OHDA rat model by M. Humbert-Claude; J.P. Guilloux; J.M. Arrang (S40-S41).
P.2.016 A possible involvement of opioid degrading enzymes in individual reactivity to acute traumatic stress by A. Kavushansky; E. Klein; D. Ben-Shachar (S41-S42).
P.2.014 Neonatal influenza A infection potentiates amphetamine induced increase in locomotor activity in the adult mouse by M. Holtze; L. Asp; H. Karlsson; S. Erhardt (S40).
P.2.013 Signaling and epigenetic mechanisms involved in the memory formation of stressful events by M. Gutiérrez Mecinas; A. Collins; J.M.H.M. Reul (S39).
P.2.012 Investigating the role of the endocannabinoid system in a rat model of distraction-induced analgesia by G.K. Ford; O. Moriarty; E. Tulley; A. Mulcahy; D.P. Finn (S38-S39).
P.2.017 Mice lacking two key phosphorylation sites on the GluR1 subunit exhibit decreased anxiety-like behaviour by C. Kiselycznyk; P. Svenningsson (S42-S43).
P.2.018 Impact of purinergic receptors in prefrontal mediated cognitive and executive functions by H. Koch; H. Franke; U. Krügel (S43-S44).
P.2.022 Exposure to antidepressant medications is not related to suicide attempts in adult depressed patients by A. Olmer; I. Iancu (S46-S47).
P.2.023 Glycine transporter 1 disruption restricted to the nucleus accumbens is sufficient to enhance latent inhibition by D. Peleg-Raibstein; J.C. Paterna; S. Schwendener; D. Boison; H. Möhler; J. Feldon; B.K. Yee (S47-S48).
P.2.021 Attentional bias to smoking related cues. A comparison of daily smokers, social smokers and non-smokers by E. Mullings; M. Munafo (S45-S46).
P.2.020 Validation of an air-puff passive avoidance paradigm to investigate aversive learning in a rat model of neuropathic pain by O. Moriarty; M. Roche; B.E. McGuire; D.P. Finn (S45).
P.2.019 Behavioral and neurochemical consequences of 5-HT transporter deletion on 5-HT2C receptor functions in mice by C. Martin; C. Chevarin; K.P. Lesch; L. Hamon; L. Lanfumey; R. Mongeau (S44).
P.2.011 Subchronic administration of phencyclidine reduces social interaction and increases aggressive-like behaviour in mice by E. Elvander-Tottie; F. Tai; S. Holst; S. Beraki; S. Wadenberg; P. Svenningsson; S.O. Ögren (S37-S38).
P.2.010 Memory-enhancing property of a new benzothiadiazine derivative, BB16: behavioural and microdialysis studies by V. Di Viesti; G. Carnevale; M. Zavatti; P. Zanoli; G. Cannazza; D. Braghiroli; M. Baraldi (S36-S37).
P.2.001 The impact of enhanced endocannabinoid neurotransmission on the food taking behaviour in rats by P. Adamczyk; A.C. McCreary; E. Przegalinski; M. Filip (S29-S30).
P.2.002 Effects of acute alcohol consumption on response inhibition: evidence of a task dependent effect by S. Adams; M.R. Munafò (S30).
P.1.032 Study of the effect of acute stress on glutamate release in prefrontal/frontal cortex of antidepressant treated rats by N. Zagaria; L. Musazzi; M. Milanesi; P. Farisello; A. Mallei; P. Baldelli; G. Racagni; F. Benfenati; G. Bonanno; M. Popoli (S27-S28).
P.1.031 Dissection of hippocampal CRH-CRHR1 signalling in early life stress-induced learning and memory deficits by X.D. Wang; G. Rammes; M. Wolf; S.H. Scharf; C. Liebl; T.Z. Baram; J.M. Deussing; M.B. Mueller; M.V. Schmidt (S27).
P.1.030 Lack of central serotonin synthesis effects on development of GABAergic subpopulations by J. Waider; S. Merker; K.P. Lesch; L. Gutknecht (S26).
P.2.003 Time dependent changes in dopamine response dynamics after chronic haloperidol treatment: an in-vivo microdialysis study by D. Amato; S. Natesan; S. Kapur; C.P. Muller (S30-S31).
P.2.004 Altered aggressive behaviour following genetic and pharmacological manipulation of serotonin autoinhibition by E. Audero; B. Mlinar; Z.K. Skachokova; A. Caprioli; R. Corradetti; C. Gross (S31-S32).
P.2.008 Duration over time of learned placebo analgesic responses by L. Colloca; F. Benedetti (S35).
P.2.009 Adolescent and adult male Wistar rats exposed to postnatal maternal separation differ in voluntary ethanol intake by L. Daoura; J. Haaker; I. Nylander (S36).
P.2.007 Pergolide attenuates memory impairment and oxidative stress in a 6-hydroxydopamine model of Parkinson's disease by A. Ciobica; L. Hritcu; V. Artenie; W. Bild; M. Padurariu (S34-S35).
P.2.006 Impulsive choice predicts resistance to extinction of cocaine seeking and enhanced vulnerability to cue-induced relapse by N. Broos; A.N.M. Schoffelmeer; T. Pattij; T.J. De Vries (S33-S34).
P.2.005 Testing the role of serotonin in the appraisal of romantic relationships in healthy adults: implications for depression by A.C. Bilderbeck; C. McCabe; F. McGlone; J. Wakeley; M. Di Simplicio; B. Godlewska; T. Harris; P.J. Cowen; R.D. Rogers (S32-S33).
Editorial Board (i).